Rate My Professor Kanneboyina Nagaraju

Kanneboyina Nagaraju serves as Dean and SUNY Distinguished Professor of Pharmaceutical Sciences at the School of Pharmacy and Pharmaceutical Sciences, Binghamton University, State University of New York. He holds a BVSc&AH (DVM equivalent) from the College of Veterinary Sciences, an MVSc from the Indian Veterinary Research Institute, and a PhD from the Sanjay Gandhi Postgraduate Institute of Medical Sciences. Nagaraju completed a Fogarty International Postdoctoral Fellowship at the National Institutes of Health before joining Johns Hopkins University School of Medicine as a tenure-track assistant professor in the Division of Rheumatology, Department of Medicine. In 2005, he moved to Children's National Hospital as associate professor of pediatrics at George Washington University School of Medicine and Health Sciences, achieving full professor with tenure in the Department of Integrative Systems Biology in 2012. He also served as interim chair of that department and director of the Research Center for Genetic Medicine. Joining Binghamton University in 2016, he founded and chaired the Department of Pharmaceutical Sciences, served as vice dean, and assumed the deanship in May 2022. He was appointed SUNY Empire Innovation Scholar in 2017 and SUNY Distinguished Professor in 2024.

His research focuses on immunology, neuromuscular diseases, autoimmune diseases, and drug development, particularly translational research in autoimmune and genetic muscle diseases. With over 200 refereed publications and textbook chapters, notable works include "Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy" (2005, Journal of Experimental Medicine), "Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy" (2008, Neurobiology of Disease), "Immune-mediated pathology in Duchenne muscular dystrophy" (2015, Science Translational Medicine), and "Targeted disruption of the acid α-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II" (1998, Journal of Biological Chemistry). Nagaraju pioneered transgenic and knockout mouse models for muscle diseases, directed preclinical drug testing, and led efforts culminating in Vamorolone (AGAMREE), an FDA- and EMA-approved dissociated glucocorticoid for Duchenne muscular dystrophy. He has secured funding from NIH, U.S. Department of Defense, and foundations, holds 10 patents, and co-founded ReveraGen BioPharma and AGADA BioSciences. He contributes to scientific advisory boards, editorial boards, and international committees like TREAT-NMD.